For research use only. Not for therapeutic Use.
<p>
SRI-011381 hydrochloride is a TGF-beta signaling agonist.
</p>
<p>
target: TGF-beta
</p>
<p>
In vitro: SRI-11381 is neuroprotective. SRI-011381 promot fibrillar Aβ clearance by macrophages, as demonstrated by the dose-dependent decreases of Aβ in the conditioned medium derived from compound-treated macrophages.
In vivo: SRI-011381 is a biologically active inducer of TGF-β signaling in cell culture and in vivo. SRI-011381 protects mice against kainic acid-induced excitotoxicity and neurodegeneration. SRI-011381 (30 mg/kg, dissolved in DMSO) is injected (ip.) into the SBE-luc mice. SRI-011381 is rapidly absorbed after oral administration to FBV mice with an oral bioavailability of approximately 50%. SRI-011381 by oral gavage of 10, 30, and 75 mg/kg for 14 days resulted in significant changes in hematological endpoints, most notably reductions in red blood cells (RBCs), hematocrit and hemoglobin. SRI-011381 reduces neurodegeneratio in APP751Lon, Swetransgenic mice.
</p>,
| Catalog Number | I005876 |
| Molecular Formula | C20H32ClN3O |
| Purity | ≥95% |
| Target | TGF-beta |
| Solubility | 10 mM in DMSO |
| Storage | Store at +4C |
| Reference | [1]. Benzyl urea derivatives for activating tgf-beta signaling. US 20160039756 A1. 2016. Feb |
